Chang Gung Memorial Hospital and University, Taiwan
Title: Cancer immunotherapy targeting glycosphingolipids (GSLs)
Alice L. Yu, MD, PhD, is an Academician of Academia Sinica, Taiwan. She is a Distinguished Chair Professor & Deputy Director of the Institute of Stem Cell & Translational Cancer Research at Chang Gung Memorial Hospital and Professor Emeritus at the University of California in San Diego.
As a pioneer in cancer immunotherapy, Dr. Yu has taken an anti-GD2 monoclonal antibody (Dinutuximab) from preclinical to phase III clinical trial, culminating in its FDA approval for the treatment of high-risk neuroblastoma in 2015. This marks the first immunotherapeutic agent to target glycolipids worldwide. She has continued to improve the efficacy of anti-GD2 immunotherapy through international collaboration. Her group has demonstrated the adverse impact of Globo H expression on the outcome of patients with hepatoma, cholangiocarcinoma, and gallbladder cancer. She also uncovered the roles of Globo H in cancer as an immune checkpoint molecule and angiogenic factor, providing rationales for the ongoing development of Globo H-targeted immunotherapeutics.
She has received many awards, including the Pediatric Oncology Award from the American Society of Clinical Oncology (ASCO) in 2020, Excellence in Technology Transfer Award from Federal Laboratory Consortium (USA) in 2016, The 55th Academic Award from the Ministry of Education (Taiwan), Year 2000 "Key to Life" Award, Leukemia & Lymphoma Society (USA), etc.
Title: Leveraging tumor-associated alterations in O-glycosylation for cancer immunotherapy
Dr. Avery Posey is an Assistant Professor at the University of Pennsylvania Perelman School of Medicine. He received Ph.D. from the University of Chicago (2011) and his postdoctoral training at the University of Pennsylvania. He is a classically trained molecular and developmental geneticist and an expert in the development and pre-clinical characterization of chimeric antigen receptors (CARs) and other engineered T cell strategies for cancer immunotherapy. His current research is focused on the redirection of T cells to target cancer-specific epitopes, especially glycan haptens and O-glycopeptide epitopes formed through altered glycosylation in cancer cells, investigation of optimal CAR-T signaling for effective anti-tumor responses and durable persistence in solid tumors, and CRISPR/Cas9-mediated gene-editing strategies for improved engineered T cells (knockout of checkpoint molecules - PD-1, CTLA-4, etc.; HDR knock-in of combination therapies). The major objective of his research is to increase the efficacy of engineered T cells in solid tumors.
Title: Regulation of the Biosynthesis of Glycopeptidolipids in Mycobacterium Abscessus
Dr. Guérardel is a senior researcher for CNRS (Lille University, France) and an Invited Professor at iGCORE (Gifu University, Japan). His research focuses on the structure-to-function relationships of complex carbohydrates, from microorganisms to higher eukaryotes, mostly in the context of host-pathogen interaction. His main objective is to understand how the glycans from both host and pathogen fine-tune the infectious process and how they may be used as diagnosis or therapeutic tools, with a keen interest in mycobacterial, fungus, and viral infections. To reach this goal, Dr. Guérardel integrates a wide range of scientific approaches, including synthetic chemistry, structural analysis using NMR spectroscopy and mass spectrometry, structural biology of proteins, and enzymology.
Title: Genome-wide Analysis of Heparan Sulfate Assembly
Dr. Ryan Weiss began his diverse scientific training by earning his B.S. in Chemistry in 2008 at Point Loma Nazarene University in San Diego, CA, USA. He then received his Ph.D. in Chemistry in 2015 at the University of California, San Diego, under the supervision of Prof. Yitzhak Tor, where he studied the design, synthesis, and application of small molecule antagonists of heparin- and heparan sulfate-protein interactions. As an NIH K12 postdoctoral fellow in Prof. Jeffrey Esko’s group at the Department of Cellular and Molecular Medicine at the University of California, San Diego, his research focused on utilizing whole-genome screening methods to investigate the regulation of heparan sulfate biosynthesis. Dr. Weiss began his independent career as an assistant professor at the Complex Carbohydrate Research Center at the University of Georgia in January 2021. Research in the Weiss Laboratory focuses on studying the structure, function, and regulation of complex carbohydrates in human biology and disease. In addition, his lab is dedicated to developing pharmacological and cell-based tools to aid in the discovery of novel targets and approaches for modulating glycan assembly in relevant human disorders.
Title: Glycans at the Frontiers of Inflammation, Autoimmunity and Cancer: mechanisms and clinical implications.
Salomé Pinho is the coordinator of the research group "Immunology, Cancer & GlycoMedicine" at the Institute for Research and Innovation in Health (i3S) at the University of Porto, Portugal, and affiliated Professor at the Medical Faculty of the University of Porto, Portugal. She developed her Ph.D. research at the Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP) and Boston University Medical School, MA, USA. She performed her postdoctoral work at IPATIMUP-University of Porto in the cancer glycobiology field. Early in her career, Dr. Pinho established a research line focusing on glycoimmunology in Inflammatory Bowel Disease. Her group focuses on understanding the role of post-translational modifications by glycosylation in the regulation of key proteins´ functions involved in cancer and chronic inflammatory conditions, envisioning potential clinical applications.
She is the Principal Investigator of several national/international grants in cancer glycobiology and inflammatory diseases. She received the Young Investigator Award from the European Association for Cancer Research and was recently distinguished by the Society for Glycobiology with the 2020 Glycobiology Significant Achievement Award.
Title: Glycosyl Hydrolases from the Seeds of Cucurbitaceae
Professor Nadimpalli is a Senior Professor in Biochemistry at University of Hyderabad, Hyderabad, India. He did his postdoctoral training at DAAD, Wuerzburg and Goettingen, Germany, and has been a faculty at University of Hyderabad since 1986.
His glyco-related contributions include development of novel affinity methods to purify mannose 6-phosphate receptors, discovery of LERP from Drosophila and lysosomal enzymes and their receptors in Hydra. He also identified and purified several plant and animal glycosidases, contributed towards understanding the physiological significance of Cucurbitaceae seed lectins and glycosidases.
His Research Interests are (1) Evolution of lysosomal biogenesis; (2) Legume and non-legume lectins-structure-function relationships; (3) Physiological functions of Plant lectins and glycosidases from legumes and non-legumes.
Professor Yasuhiro Kajihara received his Ph.D. from the Tokyo Institute of Technology in 1993. He spent two years at the Life Science Research Laboratory of Japan Tobacco Inc. as a postdoctoral fellow. In 1995 he joined Yokohama City University as an assistant professor and was then promoted to associate professor in 2001 and full professor in 2007. At YCU, he developed synthetic methods for oligosaccharides and glycoproteins. In 2009, he moved to the Department of Chemistry at Osaka University. He studies new synthetic methods of glycoproteins in order to understand how oligosaccharides regulate protein functions.
Title: Sialic acid metabolism in the gut microbiota
Dr. Juge has 25-year expertise in the molecular studies of carbohydrate-protein recognition in gut biology and microbiology, and food biotechnology. She is a deputy leader of the Gut Microbes and Health Institute Strategic Programme at the Quadram Institute Bioscience (QIB, Norwich, UK) and an elected fellow of the Royal Society of Biology. Her previous research at Marseille University (France) and Carlsberg Research Institute (Copenhagen, Denmark) focused on the structure-function relationships of plant and microbial carbohydrate-active enzymes and their potential biotechnological application. Since joining QIB in 2007, she has led a Research Group focusing on the Glycobiology of Host-Microbe interactions in the gut. Currently, her group focuses mainly on defining how gut bacteria adapt to the intestinal mucosal environment and the role of mucin glycans in the crosstalk between the gut bacteria and the host. Their work uncovered novel sialic acid metabolism pathways in gut bacteria, contributing to their fitness in the mucus niche and communication with the host. They are also interested in how cell-surface glycosylation of gut symbionts influences the host immune response. Her Lab is involved in initiatives promoting Glycosciences in Europe, such as Sweet Crosstalk or Glytunes multidisciplinary European Training Networks or CarboMet academic-industry network.
Title: Fingerprinting disease by mass spectrometry
Professor Manfred Wuhrer studied Biochemistry at Regensburg University and obtained his Ph.D. in 1999 at Giessen University, Germany. Subsequently, he joined the Leiden University Medical Center, where he was appointed assistant professor in 2005 and associate professor in 2008. In 2013, he was appointed full professor of Analytics for Biomolecular Interactions at VU University Amsterdam. In 2015 he continued his career as Head of the Center for Proteomics and Metabolomics at LUMC, Leiden. He focuses on the development of mass spectrometric methods for glycomics and glycoproteomics and their application in clinical research and biotechnology. Clinical applications cover the fields of rheumatoid arthritis, inflammatory bowel disease, colorectal cancer, prostate cancer, longevity, as well as various infectious diseases.
Title: Protein-Carbohydrate Interactions in Infection and Cancer Biology
Dr. Ute Krengel studied Chemistry in Göttingen (Germany) and obtained her Ph.D. from the University of Heidelberg in 1991 (structure and molecular mechanism of p21ras). After positions in Toronto (Canada), Groningen (The Netherlands), and Gothenburg (Sweden), she moved to Oslo (Norway), where she has held a full Professorship since 2006. She is particularly interested in molecular mechanisms of diseases, including infectious diseases and cancer, focusing on receptor interactions and enzymes. She currently serves as the Norwegian Block Allocation Group for Synchrotron Research coordinator and as a Norwegian representative of the International Glycoconjugate Organization.
@TAIPEI, AUG 27~SEP 1 2023
Meet our invited speakers for the Glyco26. To learn more about each individual speaker, please click on the photos below. Speakers are arranged by the first alphabet of surname but starting from a randomized alphabet each time.